ZURICH (Reuters) - Novartis on Monday said the U.S. Food and Drug Administration has granted breakthrough therapy status to the combination of Tafinlar and Mekinist to treat patients with BRAF V600-positive stage III melanoma following surgery.

There is a need for more effective treatment options for stage III melanoma patients at a high risk of recurrence following surgical resection, Samit Hirawat, head of global drug development at Novartis oncology unit, said in a release.

The drug MDMA is emerging as a promising tool for people suffering from post traumatic stress disorder. After years of experimental research, the Food and Drug Administration has granted breakthrough therapy status for MDMA as a potential treatment for PTSD.
More »